文献速递流行病学与生物统计临床试验与 GCP

在单病例试验中使用广义配对比较进行个体化净获益估计与荟萃分析

Individualized Net Benefit estimation and meta-analysis using generalized pairwise comparisons in N-of-1 trials.
PubMed 文献 · Stat Med · 2023-01-03

该研究将净获益(Δ)扩展至单病例试验,开发个体水平和人群水平的Δ估计量,并通过模拟PROFIL系列(38项单病例试验,测试西地那非治疗雷诺现象)评估检验效能,再以广义配对比较重新分析PROFIL。模拟显示个体和人群水平检验把握度良好,但基于真实PROFIL数据模拟时检验效能不足;个体水平Δ与贝叶斯分析的有效概率相关性好,人群水平Δ与零无显著差异。

要点

  • 广义配对比较可估计单病例试验的个体净获益并进行荟萃分析。
  • 基于真实PROFIL数据模拟时检验效能不足,即使每例重复至140天。
  • 个体水平Δ与贝叶斯有效概率相关性好,置信区间宽度相似。

核心结论

  • 广义配对比较可估计个体Δ并以荟萃分析方式聚合于单病例试验中。
  • 广义配对比较易于纳入患者偏好,支持更个性化的治疗评估,且计算时间远少于贝叶斯建模。

研究设计与样本

  • 方法学研究:开发个体水平和人群水平的Δ估计量,并进行模拟研究及对PROFIL系列(38项单病例试验,测试西地那非治疗雷诺现象)的重新分析。

主要发现

  • 零假设下模拟显示个体和人群水平检验的规模良好。
  • 基于真实PROFIL数据模拟时检验效能不足,即使将每例重复次数增加至140天。
  • PROFIL个体水平估计Δ与贝叶斯分析的有效概率相关性好,置信区间宽度相似。
  • 人群水平估计Δ与零无显著差异,与先前贝叶斯分析一致。

局限性

  • 基于真实PROFIL数据模拟时检验效能不足,即使将每例重复次数增加至140天。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Net Benefit (Δ) is a measure of the benefit-risk balance in clinical trials, based on generalized pairwise comparisons (GPC) using several prioritized outcomes and thresholds of clinical relevance. We extended Δ to N-of-1 trials, with a focus on patient-level and population-level Δ. METHODS: We developed a Δ estimator at the individual level as an extension of the stratum-specific Δ, and at the population-level as an extension of the stratified Δ. We performed a simulation study mimicking PROFIL, a series of 38 N-of-1 trials testing sildenafil in Raynaud's phenomenon, to assess the power for such an analysis with realistic data. We then reanalyzed PROFIL using GPC. This reanalysis was finally interpreted in the context of the main analysis of PROFIL which used Bayesian individual probabilities of efficacy. RESULTS: Simulations under the null showed good size of the test for both individual and population levels. The test lacked power when being simulated from the true PROFIL data, even when increasing the number of repetitions up to 140 days per patient. PROFIL individual-level estimated Δ were well correlated with the probabilities of efficacy from the Bayesian analysis while showing similarly wide confidence intervals. Population-level estimated Δ was not significantly different from zero, consistently with the previous Bayesian analysis. CONCLUSION: GPC can be used to estimate individual Δ which can then be aggregated in a meta-analytic way in N-of-1 trials. GPC ability to easily incorporate patient preferences allow for more personalized treatment evaluation, while needing much less computing time than Bayesian modeling.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Giai J, Péron J, Roustit M, et al. Individualized Net Benefit estimation and meta-analysis using generalized pairwise comparisons in N-of-1 trials. Stat Med. 2023. PMID: 36597195. doi:10.1002/sim.9648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。